Verona Pharma plc.’s (VRNA) Ensifentrine, a novel inhaled medication that acts as a dual inhibitor of both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, is under FDA review, with a decision due on June 26, 2024.Ensifentrine is proposed for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).This drug candidate has a novel mechanism in the sense that it combines bronchodilator and non-steroidal anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD.If approved, the company intends to launch Ensifentrine in the US market in the third quarter of 2024.VRNA closed Wednesday’s trading at $11.85, down 4.67%.